Results 131 to 140 of about 416,692 (196)
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial.
Lancet Infect DisLeitner DR, Walsh SR, Suzuki M, Desjardins M, Hannaford A, Sherman AC, Levine H, Carr L, Hammerness E, Osaki A, Sullivan E, Wang B, Balazs GI, Park Chang JB, Slater DM, Puri N, Kuehl CJ, Chen WH, Harris JB, Piantadosi S, Baden LR, Waldor MK, PanChol study group. +22 moreeuropepmc +1 more sourceSeroconversion and Kinetics of Vibriocidal Antibodies during the First 90 Days of Re-Vaccination with Oral Cholera Vaccine in an Endemic Population. [PDF]
Vaccines (Basel)Chisenga CC, Phiri B, Ng'ombe H, Muchimba M, Musukuma-Chifulo K, Silwamba S, Laban NM, Luchen C, Liswaniso F, Chibesa K, Mubanga C, Mwape K, Simuyandi M, Cunningham AF, Sack D, Bosomprah S. +15 moreeuropepmc +1 more sourceEffectiveness of one dose of killed oral cholera vaccine in an endemic community in the Democratic Republic of the Congo: a matched case-control study. [PDF]
Lancet Infect DisMalembaka EB, Bugeme PM, Hutchins C, Xu H, Hulse JD, Demby MN, Gallandat K, Saidi JM, Rumedeka BB, Itongwa M, Tshiwedi-Tsilabia E, Kitoga F, Bodisa-Matamu T, Kavunga-Membo H, Bengehya J, Kulondwa JC, Debes AK, Taty N, Lee EC, Lunguya O, Lessler J, Leung DT, Cumming O, Okitayemba PW, Mukadi-Bamuleka D, Knee J, Azman AS. +26 moreeuropepmc +1 more sourceMucoRice-CTB line 19A, a new marker-free transgenic rice-based cholera vaccine produced in an LED-based hydroponic system. [PDF]
Front Plant SciYuki Y, Kurokawa S, Sugiura K, Kashima K, Maruyama S, Yamanoue T, Honma A, Mejima M, Takeyama N, Kuroda M, Kozuka-Hata H, Oyama M, Masumura T, Nakahashi-Ouchida R, Fujihashi K, Hiraizumi T, Goto E, Kiyono H. +17 moreeuropepmc +1 more sourceSafety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomized, placebo-controlled trial
Leitner DR, Walsh SR, Suzuki M, Desjardins M, Hannaford A, Sherman AC, Levine H, Carr L, Hammerness E, Osaki A, Sullivan E, Wang B, Balazs GI, Park Chang JB, Slater DM, Puri N, Kuehl CJ, Chen WH, Harris JB, Piantadosi S, Baden LR, Waldor MK. +21 moreeuropepmc +1 more sourceEffectiveness of a single dose of oral cholera vaccine: findings from epidemiological and genomic surveillance ofVibrio Choleraein the Democratic Republic of the Congo (PICHA7 Program)
George CM, Namunesha A, Endres K, Felicien W, Sanvura P, Bisimwa J, Perin J, Bengehya J, Maheshe G, Cikomola C, Bisimwa L, Mwishingo A, Sack DA, Domman D. +13 moreeuropepmc +1 more sourceSafety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Lancet Glob HealthSong KR, Chapagain RH, Tamrakar D, Shrestha R, Kanodia P, Chaudhary S, Wartel TA, Yang JS, Kim DR, Lee J, Park EL, Cho H, Lee J, Thaisrivichai P, Vemula S, Kim BM, Gupta B, Saluja T, Pansuriya RK, Ganapathy R, Baik YO, Lee YJ, Jeon S, Park Y, Her HL, Park Y, Lynch JA. +26 moreeuropepmc +1 more source
